retatrutide autoimmune disorders Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide Side Effects Guide: 21

Most private providers follow criteria broadly aligned with NICE guidance: A BMI of 30 or above , or A BMI of 37 or above alongside a weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea Some providers may consider patients with a BMI slightly below these thresholds at clinical discretion

B., Scherzer R., Pietrobelli A., Lewis C

Retatrutide has attracted attention because clinical trial results have shown significant weight loss in people with obesity or overweight

Australians searching for wegovy online, for example, will find TGA-compliant pharmacy services that dispense with pharmacist oversight and deliver directly

The Cleveland Clinic highlights that weight loss achieved through GLP-1 therapy can contribute to improved blood sugar control and reduced risk of complications associated with type 2 diabetes